Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer

BACKGROUND: Novel therapies are needed to treat recurrent and advanced cervical cancer (CC), as their prognosis remains very poor. Although therapies targeting the programmed cell death protein 1 (PD-1) pathway have been approved for CC, a large subset of patients exhibit innate resistance. Using ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yumeng, Wang, Congwen, Qiu, Junjun, Qu, Xinyu, Peng, Jing, Lu, Chong, Zhang, Meng, Zhang, Mingxing, Qi, Xingling, Li, Guiling, Hua, Keqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921917/
https://www.ncbi.nlm.nih.gov/pubmed/35288463
http://dx.doi.org/10.1136/jitc-2021-003667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921917/
https://www.ncbi.nlm.nih.gov/pubmed/35288463
http://dx.doi.org/10.1136/jitc-2021-003667

Ejemplares similares